uniQure N.V - Asset Resilience Ratio
uniQure N.V (UQ1) has an Asset Resilience Ratio of 57.35% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2021–2025)
This chart shows how uniQure N.V's Asset Resilience Ratio has changed over time. Check UQ1 capital-intensive asset ratio to assess the company's strategic physical and investment asset allocation.
Liquid Assets Composition Over Time
This chart breaks down uniQure N.V's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see UQ1 market cap.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 0% |
| Short-term Investments | €446.56 Million | 57.35% |
| Total Liquid Assets | €446.56 Million | 57.35% |
Asset Resilience Insights
- Very High Liquidity: uniQure N.V maintains exceptional liquid asset reserves at 57.35% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
uniQure N.V Industry Peers by Asset Resilience Ratio
Compare uniQure N.V's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Shanghai Allist Pharmaceuticals Co. Ltd. A
SHG:688578 |
Biotechnology | 21.11% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 0.05% |
|
Sk Biopharmaceuticals Co Ltd
KO:326030 |
Biotechnology | 0.14% |
|
Tango Therapeutics Inc
NASDAQ:TNGX |
Biotechnology | 57.90% |
|
TELIX Pharmaceuticals Ltd
AU:TLX |
Biotechnology | 32.29% |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278 |
Biotechnology | 4.69% |
|
Hangzhou Biotest Biotech Co Ltd
SHG:688767 |
Biotechnology | 0.56% |
|
Theravance Biopharma Inc
F:0TB |
Biotechnology | 37.29% |
Annual Asset Resilience Ratio for uniQure N.V (2021–2025)
The table below shows the annual Asset Resilience Ratio data for uniQure N.V.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 65.74% | €542.30 Million ≈ $634.01 Million |
€824.91 Million ≈ $964.40 Million |
+28.26pp |
| 2024-12-31 | 37.48% | €208.59 Million ≈ $243.86 Million |
€556.54 Million ≈ $650.65 Million |
-7.79pp |
| 2023-12-31 | 45.27% | €376.53 Million ≈ $440.21 Million |
€831.69 Million ≈ $972.33 Million |
+27.57pp |
| 2022-12-31 | 17.71% | €124.83 Million ≈ $145.94 Million |
€704.96 Million ≈ $824.18 Million |
-- |
| 2021-12-31 | 0.00% | €0.00 ≈ $0.00 |
€809.18 Million ≈ $946.02 Million |
-- |
About uniQure N.V
uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases in the United States. The company offers HEMGENIX that allows people living with hemophilia B to produce factor IX, which can lower the risk of bleeding. Its lead product candidate is AMT-130, a gene therapy candidate, which is in Phase I/II clinical study for the treatment of Huntington's disease. Th… Read more